Abstract
The special protocol assessment introduced only six years ago by the US Food and Drug Administration (FDA) to facilitate clinical trials is gaining popularity. Randy Osborne finds out why.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have